In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
The transaction is expected to close in the first quarter of 2022
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Subscribe To Our Newsletter & Stay Updated
